Journal
WORLD JOURNAL OF GASTROENTEROLOGY
Volume 27, Issue 11, Pages 1022-1042Publisher
BAISHIDENG PUBLISHING GROUP INC
DOI: 10.3748/wjg.v27.i11.1022
Keywords
Inflammatory bowel disease; SARS-CoV-2; COVID-19; Crohn disease; Colitis ulcerative; Biological therapy
Categories
Ask authors/readers for more resources
Managing inflammatory bowel disease (IBD) during the COVID-19 pandemic presents challenges for clinicians and patients, especially regarding the use of biologics and immunosuppressive agents, and the impact of SARS-CoV-2 infection on patients.
Managing inflammatory bowel disease (IBD) during the coronavirus disease 2019 (COVID-19) pandemic has been a challenge faced by clinicians and their patients, especially concerning whether to proceed with biologics and immunosuppressive agents in the background of a global outbreak of a highly contagious new coronavirus (severe acute respiratory syndrome coronavirus 2, SARS-CoV-2). The knowledge about the impact of this virus on patients with IBD, although it is still scarce, is rapidly evolving. In particular, concerns surrounding medications' impact for IBD on the risk of acquiring SARS-CoV-2 infection or developing COVID-19, and potentially exacerbate viral replication and the COVID-19 course, are a current thinking of both practicing clinicians and providers caring for patients with IBD. Managing patients with IBD infected with SARS-CoV-2 depends on both the clinical activity of the IBD and the occasional development and severity of COVID-19. In this review, we summarize the current data regarding gastrointestinal involvement by SARS-CoV-2 and pharmacologic and surgical management for IBD concerning this infection, and the COVID-19 impact on both the patient's psychological functioning and endoscopy services, and we concisely summarize the telemedicine roles during the COVID-19 pandemic.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available